Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used

被引:34
作者
Caballeria, Llorenc [1 ,2 ]
Pera, Guillem [1 ]
Rodriguez, Lluis [1 ]
Antonia Auladell, Maria [1 ,2 ]
Bernad, Jesus [3 ]
Canut, Santiago [4 ]
Toran, Pere [1 ,5 ]
机构
[1] CAP El Maresme, IDIAP Jordi Gol, Primary Healthcare Res Support Unit Metropolitana, Barcelona 08303, Spain
[2] Primary Healthcare Ctr Premia de Mar, Barcelona, Spain
[3] Primary Healthcare Ctr Vilassar de Mar, Barcelona, Spain
[4] Primary Healthcare Ctr Vilassar de Dalt, Barcelona, Spain
[5] Primary Healthcare Ctr Gatassa, Catalan Hlth Inst, Barcelona, Spain
关键词
arterial hypertension; cholesterol; diabetes; obesity; triglycerides; ultrasonography; STEATOHEPATITIS; PREDICTOR; RISK;
D O I
10.1097/MEG.0b013e328355b87f
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Objective Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and it is considered the hepatic component of the metabolic syndrome (MetS). The WHO, the National Cholesterol Education Program (NCEP) and the International Diabetes Federation (IDF) have different criteria to define MetS. The aim of this study was to analyze the association between NAFLD and MetS using the three existing criteria. Methods Cross-sectional, descriptive population-based study derived from a previous study on the prevalence and factors associated with NAFLD in Spain. Results A total of 696 individuals [mean age 53 +/- 14 years (range 17-83 years)] were included, 59% of whom were women. The prevalence of MetS was 34.2% according to the IDF, 17.7% according to the NCEP and 15.5% according to the WHO. Concordance among the different criteria was between 76 and 87%, with kappa indexes between 0.39 and 0.54. NAFLD was present in 184 individuals according to echographic criteria (prevalence 26.4%). The prevalence of NAFLD among patients with MetS was 43% (IDF), 53% (NCEP) and 64% (WHO). The odds ratio (95% confidence interval) for a logistic regression using NAFLD as a dependent variable varied from 3.44 (2.42-4.88) for IDF to 7.28 (4.68-11.3) for WHO, being 4.28 (2.84-6.43) for NCEP. Conclusion The MetS is quite frequent in the general population, although its prevalence varies considerably according to the criteria used for its definition. The MetS is associated with NAFLD, with the WHO definition being the best to determine its presence, probably because of the inclusion of insulin resistance as a main component. Unification of criteria is needed to adequately compare the prevalence of MetS and its relationship with NAFLD in different population groups. Eur J Gastroenterol Hepatol 24: 1007-1011 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:1007 / 1011
页数:5
相关论文
共 21 条
[1]
The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]
Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[3]
Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain [J].
Caballeria, Llorenc ;
Pera, Guillem ;
Antonia Auladell, Maria ;
Toran, Pere ;
Munoz, Laura ;
Miranda, Dolores ;
Aluma, Alba ;
Dario Casas, Jose ;
Sanchez, Carmen ;
Gil, Dolors ;
Auba, Josep ;
Tibau, Albert ;
Canut, Santiago ;
Bernad, Jesus ;
Maite Aizpurua, Miren .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (01) :24-32
[4]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]
The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[6]
Fatty Liver: Think Globally [J].
Everhart, James E. ;
Bambha, Kiran M. .
HEPATOLOGY, 2010, 51 (05) :1491-1493
[7]
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications [J].
Fabbrini, Elisa ;
Sullivan, Shelby ;
Klein, Samuel .
HEPATOLOGY, 2010, 51 (02) :679-689
[8]
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]
Nonalcoholic fatty liver disease in severely obese subjects [J].
Gholam, Pierre M. ;
Flancbaum, Louis ;
Machan, Jason T. ;
Charney, Douglas A. ;
Kotler, Donald P. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (02) :399-408
[10]
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease [J].
Hamaguchi, M ;
Kojima, T ;
Takeda, N ;
Nakagawa, T ;
Taniguchi, H ;
Fujii, K ;
Omatsu, T ;
Nakajima, T ;
Sarui, H ;
Shimazaki, M ;
Kato, T ;
Okuda, J ;
Ida, K .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (10) :722-728